Maravai Historical Financial Ratios
MRVI Stock | USD 5.81 0.23 4.12% |
Maravai Lifesciences is lately reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 45.78 will help investors to properly organize and evaluate Maravai Lifesciences financial condition quickly.
Maravai |
About Maravai Financial Ratios Analysis
Maravai LifesciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Maravai Lifesciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Maravai financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Maravai Lifesciences history.
Maravai Lifesciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Maravai Lifesciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Maravai Lifesciences sales, a figure that is much harder to manipulate than other Maravai Lifesciences Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Maravai Lifesciences Holdings dividend as a percentage of Maravai Lifesciences stock price. Maravai Lifesciences dividend yield is a measure of Maravai Lifesciences stock productivity, which can be interpreted as interest rate earned on an Maravai Lifesciences investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Maravai Lifesciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. As of now, Maravai Lifesciences' Capex To Depreciation is increasing as compared to previous years. The Maravai Lifesciences' current Inventory Turnover is estimated to increase to 3.83, while Price To Sales Ratio is projected to decrease to 2.84.
2023 | 2024 (projected) | Dividend Yield | 0.0176 | 0.0157 | Price To Sales Ratio | 2.99 | 2.84 |
Maravai Lifesciences fundamentals Correlations
Click cells to compare fundamentals
Maravai Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Maravai Lifesciences fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 20.15 | 9.54 | 6.02 | 2.13 | 2.99 | 2.84 | |
Ptb Ratio | 20.4 | 30.63 | 15.24 | 3.45 | 2.07 | 1.97 | |
Days Sales Outstanding | 45.98 | 65.55 | 53.67 | 60.69 | 70.39 | 45.78 | |
Book Value Per Share | 1.5 | 1.6 | 4.75 | 6.88 | 5.99 | 6.29 | |
Free Cash Flow Yield | 0.002415 | 0.0468 | 0.0735 | 0.28 | 0.0702 | 0.0623 | |
Operating Cash Flow Per Share | 0.25 | 1.57 | 3.21 | 4.07 | 0.96 | 1.34 | |
Stock Based Compensation To Revenue | 0.0117 | 0.0867 | 0.0131 | 0.0211 | 0.12 | 0.13 | |
Capex To Depreciation | 0.71 | 0.98 | 0.6 | 0.45 | 1.34 | 1.41 | |
Pb Ratio | 20.4 | 30.63 | 15.24 | 3.45 | 2.07 | 1.97 | |
Ev To Sales | 22.71 | 10.79 | 6.0 | 2.08 | 3.12 | 2.96 | |
Free Cash Flow Per Share | 0.0721 | 1.31 | 3.08 | 3.94 | 0.46 | 0.44 | |
Roic | 0.0445 | 0.1 | 0.58 | 0.48 | 0.007535 | 0.007158 | |
Inventory Turnover | 4.71 | 2.39 | 2.73 | 3.92 | 2.89 | 3.83 | |
Net Income Per Share | (0.0538) | 0.8 | 4.09 | 3.73 | (0.9) | (0.86) | |
Days Of Inventory On Hand | 77.54 | 152.61 | 133.88 | 93.22 | 126.12 | 89.24 | |
Payables Turnover | 8.94 | 26.68 | 17.24 | 28.2 | 13.86 | 14.9 | |
Research And Ddevelopement To Revenue | 0.0253 | 0.0327 | 0.019 | 0.0208 | 0.0598 | 0.0628 | |
Capex To Revenue | 0.12 | 0.0894 | 0.0186 | 0.0194 | 0.23 | 0.24 | |
Cash Per Share | 0.26 | 2.44 | 4.8 | 4.81 | 4.36 | 2.26 | |
Pocfratio | 119.63 | 17.81 | 13.05 | 3.51 | 6.85 | 7.19 | |
Interest Coverage | 0.8 | 2.2 | 18.33 | 28.13 | (0.69) | (0.66) | |
Capex To Operating Cash Flow | 0.71 | 0.17 | 0.0403 | 0.0319 | 0.52 | 0.55 | |
Pfcf Ratio | 414.08 | 21.38 | 13.6 | 3.63 | 14.24 | 14.95 | |
Days Payables Outstanding | 40.83 | 13.68 | 21.17 | 12.94 | 26.33 | 25.05 | |
Income Quality | (4.64) | 1.93 | 0.79 | 1.09 | (1.06) | (1.01) | |
Roe | (0.0368) | 0.87 | 1.49 | 0.9 | (0.29) | (0.27) | |
Ev To Operating Cash Flow | 134.79 | 20.14 | 13.0 | 3.42 | 7.13 | 7.49 | |
Pe Ratio | (554.68) | 35.26 | 10.25 | 3.84 | (7.26) | (7.62) | |
Ev To Free Cash Flow | 466.54 | 24.18 | 13.55 | 3.54 | 14.84 | 15.58 | |
Earnings Yield | (0.001803) | 0.0284 | 0.0976 | 0.26 | (0.14) | (0.13) | |
Intangibles To Total Assets | 0.73 | 0.32 | 0.14 | 0.22 | 0.37 | 0.47 | |
Net Debt To E B I T D A | 7.58 | 2.56 | (0.029) | (0.0768) | 0.0505 | 0.048 | |
Current Ratio | 2.05 | 2.54 | 7.89 | 7.7 | 8.0 | 8.4 | |
Tangible Book Value Per Share | (2.87) | (2.56) | 2.4 | 3.08 | 1.84 | 1.93 | |
Receivables Turnover | 7.94 | 5.57 | 6.8 | 6.01 | 5.19 | 7.19 | |
Graham Number | 1.33 | 4.05 | 15.9 | 18.65 | 8.01 | 6.75 | |
Shareholders Equity Per Share | 1.46 | 0.92 | 2.75 | 4.14 | 3.16 | 1.87 | |
Debt To Equity | 2.39 | 6.04 | 1.68 | 0.97 | 1.26 | 1.19 |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.